Cargando…

Revolutionizing Alzheimer's disease and clinical trials through biomarkers

The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattsson, Niklas, Carrillo, Maria C., Dean, Robert A., Devous, Michael D., Nikolcheva, Tania, Pesini, Pedro, Salter, Hugh, Potter, William Z., Sperling, Reisa S., Bateman, Randall J., Bain, Lisa J., Liu, Enchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/
https://www.ncbi.nlm.nih.gov/pubmed/27239522
http://dx.doi.org/10.1016/j.dadm.2015.09.001
_version_ 1782433679154348032
author Mattsson, Niklas
Carrillo, Maria C.
Dean, Robert A.
Devous, Michael D.
Nikolcheva, Tania
Pesini, Pedro
Salter, Hugh
Potter, William Z.
Sperling, Reisa S.
Bateman, Randall J.
Bain, Lisa J.
Liu, Enchi
author_facet Mattsson, Niklas
Carrillo, Maria C.
Dean, Robert A.
Devous, Michael D.
Nikolcheva, Tania
Pesini, Pedro
Salter, Hugh
Potter, William Z.
Sperling, Reisa S.
Bateman, Randall J.
Bain, Lisa J.
Liu, Enchi
author_sort Mattsson, Niklas
collection PubMed
description The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.
format Online
Article
Text
id pubmed-4879481
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48794812016-05-27 Revolutionizing Alzheimer's disease and clinical trials through biomarkers Mattsson, Niklas Carrillo, Maria C. Dean, Robert A. Devous, Michael D. Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z. Sperling, Reisa S. Bateman, Randall J. Bain, Lisa J. Liu, Enchi Alzheimers Dement (Amst) Diagnostic Assessment & Prognosis The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts. Elsevier 2015-10-03 /pmc/articles/PMC4879481/ /pubmed/27239522 http://dx.doi.org/10.1016/j.dadm.2015.09.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Diagnostic Assessment & Prognosis
Mattsson, Niklas
Carrillo, Maria C.
Dean, Robert A.
Devous, Michael D.
Nikolcheva, Tania
Pesini, Pedro
Salter, Hugh
Potter, William Z.
Sperling, Reisa S.
Bateman, Randall J.
Bain, Lisa J.
Liu, Enchi
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title_full Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title_fullStr Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title_full_unstemmed Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title_short Revolutionizing Alzheimer's disease and clinical trials through biomarkers
title_sort revolutionizing alzheimer's disease and clinical trials through biomarkers
topic Diagnostic Assessment & Prognosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/
https://www.ncbi.nlm.nih.gov/pubmed/27239522
http://dx.doi.org/10.1016/j.dadm.2015.09.001
work_keys_str_mv AT mattssonniklas revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT carrillomariac revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT deanroberta revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT devousmichaeld revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT nikolchevatania revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT pesinipedro revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT salterhugh revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT potterwilliamz revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT sperlingreisas revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT batemanrandallj revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT bainlisaj revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers
AT liuenchi revolutionizingalzheimersdiseaseandclinicaltrialsthroughbiomarkers